Pediatric Neuroinflammatory and Neuropsychiatric Syndromes Associated with Dupilumab Treatment for Atopic Dermatitis.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 42309223.
- Also identified by DOI 10.1016/j.jpeds.2026.115201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dupilumab, a monoclonal antibody blocking interleukin-4/interleukin-13 signaling, was associated with neuroinflammatory syndromes in 4 children treated for atopic dermatitis. Individuals exhibited behavioral changes, language impairment, and neurodiagnostic abnormalities 2-6 months after treatment initiation. Three improved with drug discontinuation and immunomodulatory therapy; 1 with pre-existing X-linked adrenoleukodystrophy required stem cell transplantation.